OIS@ASRS 2017 Videos

Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona,delivers a frank overview of the pipeline of experimental retinal drugs. The next year could be critical…

Mark S. Blumenkranz, MD, MMS, thanks many for the “humbling honor” of winning the OIS Lifetime Innovator Award. Dr. Blumenkranz, the chairman and managing director…

What retinal diseases are most interesting to Allergan? C. David Nicholson, PhD, chief R&D officer, discusses Allergan’s Phase III trials of Abicipar, a promising treatment…

Firas M. Rahhal, MD, a partner at ExSight Capital, had his hands full with his surgery practice in LA. But when a few high-profile patients…

Christy Shaffer, PhD, general partner at Hatteras Venture Partners, didn’t have a career map that led her into the corner office at Inspire Pharmaceuticals or…

In 2011, Cal Roberts, MD, got an unexpected call from Brent Saunders, then head of Bausch & Lomb. Saunders asked if Dr. Roberts would trade…

From injection of drug agents into the suprachoroidal space surrounding the eye to a port for injection of anti-VEGF therapy, a number of companies in…

Mark Humayun, MD, PhD, professor of ophthalmology at the University of Southern California, moderates a panel on combination drug delivery in age-related macular degeneration and…

Who inspires The Inspired? In an interview following his receiving the OIS Lifetime Innovator Award at OIS@ASRS in Boston, Mark S. Blumenkranz, MD, MMS, the…

Andrew Gitkin, head of West Coast biotechnology investment banking at Piper Jaffray, examines first-half performance of critical markets. Also, what impact is Washington’s intransigence having…

What could the acquisition of TearScience and Kala Pharmaceuticals mean for the broader M&A and IPO activity? We ask Andrew Gitkin, managing director and head…

Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, discusses a promising new technology that could enable much earlier detection…